Programmable Genetic Medicines

Gene editing has left the lab: CRISPR and base-editing platforms can now write therapies, while sequencing and liquid biopsy find the patients. That stack sits on the steep part of the adoption curve in a precision-medicine TAM traditional small-molecule pharma cannot cover. We accept 50% drawdowns in the pure plays for multi-year upside as writing, reading, and delivering genetic information becomes standard of care, with scaled innovators and toolmakers funding the category rather than today’s multiples. Launch basket (equal weight): CRSP, BEAM, ILMN, GH, NTRA, MRNA, TMO, LLY, AMGN, MRK Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.